Detailed description page of THPdb

This page displays user query in tabular form.

1423 details

Primary information
ThPP ID	Th1071
Therapeutic Peptide/Protein Name	Pancrelipase
Sequence	Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	131125.6
Chemical Formula	C5850H8902N1606O1739S49
Isoelectric Point	7.44
Hydrophobicity	N.A.
Melting Point (℃)	48-51
Half Life	Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description	Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease	For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics	Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action	The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity	Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism	Pancrelipase acts locally, so there is minimal metabolism.
Absorption	Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution	N.A.
Clearance	Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories	Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Viokace
Company	Aptalis Pharma US, Inc.
Brand Discription	VIOKACE is a pancreatic enzyme preparation for oral administration consisting of pancrelipase, an extract derived fromÂ porcineÂ pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, amylases, and proteases.
Prescribed for	VIOKACE (pancrelipase) tablets, in combination with a proton pump inhibitor, is indicated in adults for the treatment ofÂ exocrineÂ paencratic insufficiencydue toÂ chronic pancreatitisÂ orÂ pancreatectomy.
Chemical Name	N.A.
Formulation	10,440 USP units of lipase;Â 39,150 USP units of protease; 39,150 USP units of amylase tablets are tan, round biconvex and have VIO9111 engraved on one side and 9111 on the other side.Inactive ingredients in VIOKACE include: colloidal silicon dioxide, crosscarmellose sodium, lactose monohydrate, microcrystalline cellulose, stearic acid and talc.
Physcial Appearnce	Pancrelipase is a beige-white amorphous powder. It is miscible in water and practically insoluble in alcohol and converted to tablet form
Route of Administration	Oral route
Recommended Dosage	Enzyme dosing should begin with 500 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Contraindication	None
Side Effects	The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include fibrosing colonopathy, hyperuricemiaÂ and allergic reactions.
Useful Link	http://www.rxlist.com/viokace-drug.htm
PubMed ID	28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure	Th1071 (View) or (Download)